Statin therapy - what now?
- 1 March 2001
- journal article
- review article
- Published by BMJ in Drug and Therapeutics Bulletin
- Vol. 39 (3) , 17-21
- https://doi.org/10.1136/dtb.2001.39317
Abstract
In England, only 30% of patients with established coronary heart disease (CHD) and raised serum lipids, and fewer than 4% of individuals eligible for primary prevention, receive lipid-lowering therapy.1 Target total cholesterol concentrations are achieved in fewer than 50% of patients who do receive such treatment.1 Here, we review the use of statin therapy in the prevention of CHD events.Keywords
This publication has 22 references indexed in Scilit:
- Effect of Statins on Risk of Coronary DiseaseJAMA, 1999
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsNew England Journal of Medicine, 1998
- Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol LevelsJAMA, 1998
- Comparative Dose Efficacy Study of Atorvastatin Versus Simvastatin, Pravastatin, Lovastatin, and Fluvastatin in Patients With Hypercholesterolemia (The CURVES Study) fn1fn1This study was supported by Parke-Davis, Division of Warner Lambert Company, Morris Plains, New Jersey. Manuscript received August 20, 1997; revised manuscript received and accepted November 24, 1997.The American Journal of Cardiology, 1998
- Cholesterol Lowering With Statin Drugs, Risk of Stroke, and Total MortalityJAMA, 1997
- The Sheffield table for primary prevention of coronary heart disease: correctedThe Lancet, 1996
- The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol LevelsNew England Journal of Medicine, 1996
- Targeting lipid-lowering drug therapy for primary prevention of coronary disease: an updated Sheffield tableThe Lancet, 1996
- Prevention of Coronary Heart Disease with Pravastatin in Men with HypercholesterolemiaNew England Journal of Medicine, 1995
- Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of diseaseThe Lancet, 1994